Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.74 |
| ▸ | NPC1 | O15118 | 14/20 | 0.74 |
| ▸ | GFER | P55789 | 4/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | TP53 | P04637 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.67 |
| ▸ | RELA | Q04206 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894063 | 0.99 | RAB9A (0.72) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL17199136 | 0.88 | NPC1 (0.74) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL2488592 | 0.87 | RAB9A (0.96) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL30296348 | 0.87 | RAB9A (0.96) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL29404722 | 0.86 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL1852701 | 0.86 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL31696797 | 0.86 | RAB9A (0.93) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL5376393 | 0.85 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL2244350 | 0.85 | NPC1 (0.65) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL25026542 | 0.84 | HDAC3 (0.60) | RAB9ANPC1GFERRXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| WO-2023146844-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230234931-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | UNIVERSITY OF HOUSTON SYSTEM | 2023-07-27 | — | — | US | disclosed |
| US-20230233531-A1 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | UNIVERSITY OF HOUSTON SYSTEM | 2023-07-27 | — | — | US | disclosed |
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-25 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233531-A1 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | PTGES, PTGES2, PTGES3 | RAB9A 4016/4885NPC1 1269/4885GFER 3377/4885 |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | RAB9A 2271/4885NPC1 59/4885GFER 3619/4885 |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | PTGES, PTGS1, PTGIS | RAB9A 2347/4885NPC1 1063/4885GFER 899/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885GFER 4513/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | RAB9A 2198/4885NPC1 4082/4885GFER 670/4885 |
| US-20230234931-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | PTGES, PTGES2, PTGS1 | RAB9A 4809/4885NPC1 1949/4885GFER 1128/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885GFER 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.